26820-61-1

Basic information

• Product Name: 5-Nitro-2-piperidinopyridine
• Synonyms: 5-Nitro-2-piperidinopyridine;2-Piperidino-5-nitropyridine;NSC102511;5-Nitro-2-(piperidine-1-yl)pyridine
• CAS NO: 26820-61-1
• Molecular Formula: C₁₀H₁₃N₃O₂
• Molecular Weight: 207.23
• Mol File: 26820-61-1.mol
• Article Data: 19

Chemical Properties

• Melting Point: 83-84℃
• Boiling Point: 380.4 °C at 760 mmHg
• Flash Point: 183.9 °C
• Appearance: /
• Density: 1.242
• Vapor Pressure: 5.45E-06mmHg at 25°C
• Refractive Index: 1.582
• PKA: 4.63±0.29(Predicted)
• CAS DataBase Reference: 5-Nitro-2-piperidinopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Nitro-2-piperidinopyridine(26820-61-1)
• EPA Substance Registry System: 5-Nitro-2-piperidinopyridine(26820-61-1)

Safety Data

• Hazardous Substances Data: 26820-61-1(Hazardous Substances Data)

Usage

General Description

5-Nitro-2-piperidinopyridine is a chemical compound with the formula C10H12N4O2. It is a nitro-containing heterocyclic compound that is used in the synthesis of pharmaceuticals and agrochemicals. This chemical may be used as an intermediate in the production of antiparasitic drugs and other biologically active compounds. It is a yellow crystalline powder that is soluble in organic solvents. Due to its potential for use in the pharmaceutical and agrochemical industries, 5-Nitro-2-piperidinopyridine is an important chemical compound in organic synthesis.

InChI:InChI=1/C10H13N3O2/c14-13(15)9-4-5-10(11-8-9)12-6-2-1-3-7-12/h4-5,8H,1-3,6-7H2

Upstream product

• 110-89-4 piperidine 
• 4548-45-2 2-chloro-5-nitropyridine 
• 5446-92-4 2-methoxy-5-nitropyridine 
• 99073-54-8 (5-nitro-[2]pyridyl)-[3]pyridyl ether 
• 42259-31-4 1,1-bis(piperidinyl)ethylene 
• 14080-32-1 5-nitropyrimidine 
• 5418-51-9 5-nitro-2-pyridone 
• 4487-59-6 2-bromo-5-nitropyridine 
• 28222-02-8 3-nitro-6-phenoxypyridine 
• 7440-44-0 pyrographite 
• 2530-26-9 3-nitropyridine 
• 145771-10-4 2-(5-Nitro-pyridin-2-yl)-5-oxo-2,5-dihydro-isoxazole-4-carboxylic acid ethyl ester 

Downstream Products

• 55403-29-7 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-5'-ylamine 

Relevant articles and documents

Room-Temperature Amination of Chloroheteroarenes in Water by a Recyclable Copper(II)-Phosphaadamantanium Sulfonate System

Buchwald-Hartwig amination of chloroheteroarenes has been a challenging synthetic process, with very few protocols promoting this important transformation at ambient temperature. The current report discusses about an efficient copper-based catalytic system (Cu/PTABS) for the amination of chloroheteroarenes at ambient temperature in water as the sole reaction solvent, a combination that is first to be reported. A wide variety of chloroheteroarenes could be coupled efficiently with primary and secondary amines as well as selected amino acid esters under mild reaction conditions. Catalytic efficiency of the developed protocol also promotes late-stage functionalization of active pharmaceutical ingredients (APIs) such as antibiotics (floxacins) and anticancer drugs. The catalytic system also performs efficiently at a very low concentration of 0.0001 mol % (TON = 980,000) and can be recycled 12 times without any appreciable loss in activity. Theoretical calculations reveal that the π-acceptor ability of the ligand PTABS is the main reason for the appreciably high reactivity of the catalytic system. Preliminary characterization of the catalytic species in the reaction was carried out using UV-VIS and ESR spectroscopy, providing evidence for the Cu(II) oxidation state.

N-heteroarylsulfonamide derivative, and preparation and application of same

The invention provides an N-heteroarylsulfonamide derivative, and preparation and an application of same. The derivative includes pharmaceutically acceptable salts and solvates thereof; a test provesthat the N-heteroarylsulfonamide derivative allows specific combination and inhibit or reduce the activity of potassium pathway Kv1.3, so that the derivative can be used for treating autoimmune diseases, caused by abnormal activation of the potassium pathway Kv1.3, of human or animal. An inhibitor in the invention also includes a medicinal composition of the compound. The invention also provides amethod for preparing the compound. The derivative has the general formula as the specification.

First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent

Kinase irregularity has been correlated with several complex neurodegenerative tauopathies. Development of selective inhibitors of these kinases might afford promising anti-tauopathy therapies. While DAPK1 inhibitors halt the formation of tau aggregates and counteract neuronal death, CSF1R inhibitors could alleviate the tauopathies-associated neuroinflammation. Herein, we report the design, synthesis, biological evaluation, mechanistic study, and molecular docking study of novel CSF1R/DAPK1 dual inhibitors as multifunctional molecules inhibiting the formation of tau aggregates and neuroinflammation. Compound 3l, the most potent DAPK1 inhibitor in the in vitro kinase assay (IC50 = 1.25 μM) was the most effective tau aggregates formation inhibitor in the cellular assay (IC50 = 5.0 μM). Also, compound 3l elicited potent inhibition of CSF1R in the in vitro kinase assay (IC50 = 0.15 μM) and promising inhibition of nitric oxide production in LPS-induced BV-2 cells (55% inhibition at 10 μM concentration). Kinase profiling and hERG binding assay anticipated the absence of off-target toxicities while the PAMPA-BBB assay predicted potentially high BBB permeability. The mechanistic study and selectivity profile suggest compound 3l as a non-ATP-competitive DAPK1 inhibitor and an ATP-competitive CSF1R inhibitor while the in silico calculations illustrated binding of compound 3l to the substrate-binding site of DAPK1. Hence, compound 3l might act as a protein-protein interaction inhibitor by hindering DAPK1 kinase reaction through preventing the binding of DAPK1 substrates.